Assessing the effects of diabetes mellitus on the monocyte-to-lymphocyte ratio and the QuantiFERON-TB gold plus assays for tuberculosis treatment monitoring: a prospective cohort study.

ABSTRACT: Diabetes mellitus (DM) is an important risk factor for the development of active tuberculosis (TB). QuantiFERON-TB Gold Plus (QFT-P), white blood cell count (WBC) assays and monocyte-to-lymphocyte ratio (MLR) reflect the inflammatory reactions associated with TB and offer the potential to monitor TB treatment to allow a better management of the disease. The aim of this study was to assess the influence of DM on the respective performances of QFT-P and WBC assays in their capacities to monitor the treatment of drug-sensitive pulmonary TB (TBP). The QFT-P and WBC were prospectively compared between TB patients with and without DM at inclusion (D0), at the end of treatment (M6) and two months after the end of treatment (M8). After laboratory measurement of glycated hemoglobin (HbA1c), the pat

SUBMITTER: Ranaivomanana P 

PROVIDER: S-EPMC11782029 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature